The profound influence of GLP-1 receptor agonists on cardiovascular outcomes has been elucidated through a series of CVOTs
After four weeks of testing, interviews with experts, and debates among panelists, the consensus was clear: DUAs products arent staging the coup that our wallets were hoping for
At the time of writing, Novo Nordisk is worth $599 billion (464bn)
Fueled by rising demand for weight loss drugs, FDA approvals for Wegovy and Zepbound, and mounting evidence of long-term health benefits, obesity prescriptions are outpacing those for diabetes in many countries
Shifting your injection to a day that makes the peak tiredness window less disruptive - a Friday injection means the worst of it falls over the weekend, for example - is a simple practical adjustment that makes a real difference for some people
Animal models lacking the GLP-1 receptor (GLP-1R) have higher fasting plasma glucose and a decreased ability to clear glucose in response to a meal [8]
